Association of the Reduced Function Met420del Polymorphism of SLC22A1 with Metformin-Induced Gastrointestinal Intolerance in Ethiopian Patients with Type 2 Diabetes Mellitus

References

• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379. doi:10.2337/dc12-0413
   PubMed Web of Science ®Google Scholar
• Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab. 1991;17(1 Pt 2):224–231.
   PubMedGoogle Scholar
• DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281–303. doi:10.7326/0003-4819-131-4-199908170-00008
   PubMed Web of Science ®Google Scholar
• Overbeek JA, Heintjes EM, Prieto-Alhambra D, et al. Type 2 diabetes mellitus treatment patterns across Europe: a population-based multi-database study. Clin Ther. 2017;39(4):759–770. doi:10.1016/j.clinthera.2017.02.008
   PubMed Web of Science ®Google Scholar
• Lukas L, Andreas M, Willi O, et al. Prescription of oral antidiabetic drugs in Tyrol - Data from the Tyrol diabetes registry 2012–2015. Wien Klin Wochenschr. 2017;129(1–2). doi:10.1007/s00508-016-1135-1
   Web of Science ®Google Scholar
• Tanabe M, Motonaga R, Terawaki Y, Nomiyama T, Yanase T. Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. J Diabetes Investig. 2017;8(2):227–234. doi:10.1111/jdi.12567
   PubMed Web of Science ®Google Scholar
• Holt R. Personalized medicine for diabetes: a special issue. Diabet Med. 2016;33:711. doi:10.1111/dme.13144
   PubMedGoogle Scholar
• Pearson ER. Personalized medicine in diabetes: the role of “omics” and biomarkers. Diabet Med J Br Diabet Assoc. 2016;33(6):712–717. doi:10.1111/dme.13075
   PubMed Web of Science ®Google Scholar
• Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin pharmacogenomics: current status and future directions. Diabetes. 2014;63(8):2590–2599. doi:10.2337/db13-1367
   PubMed Web of Science ®Google Scholar
• Todd JN, Florez JC. An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics. 2014;15(4):529–539. doi:10.2217/pgs.14.21
   PubMed Web of Science ®Google Scholar
• Dujic T, Zhou K, Yee SW, et al. Variants in pharmacokinetic transporters and glycemic response to metformin: a metgen meta-analysis. Clin Pharmacol Ther. 2017;101(6):763–772. doi:10.1002/cpt.567
   PubMed Web of Science ®Google Scholar
• Hiroshi T, Eriko S, Kenji O, Shun H, Ichiro I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics. 2008;9(4). doi:10.2217/14622416.9.4.415
   Web of Science ®Google Scholar
• Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009;9(4):242–247. doi:10.1038/tpj.2009.15
   PubMed Web of Science ®Google Scholar
• Tarasova L, Kalnina I, Geldnere K, et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genomics. 2012;22(9):659–666. doi:10.1097/FPC.0b013e3283561666
   PubMed Web of Science ®Google Scholar
• Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CNA, Pearson ER. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes. 2015;64(5):1786–1793. doi:10.2337/db14-1388
   PubMed Web of Science ®Google Scholar
• Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica Fate Foreign Compd Biol Syst. 1994;24(1):49–57. doi:10.3109/00498259409043220
   PubMed Web of Science ®Google Scholar
• Khatami F, Mohajeri-Tehrani MR, Tavangar SM. The importance of precision medicine in type 2 diabetes mellitus (T2DM): from pharmacogenetic and pharmacoepigenetic aspects. Endocr Metab Immune Disord Drug Targets. 2019;19(6):719–731. doi:10.2174/1871530319666190228102212
   PubMed Web of Science ®Google Scholar
• Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017;19(4):473–481. doi:10.1111/dom.12854
   PubMed Web of Science ®Google Scholar
• Díaz-Perdigones CM, Muñoz-Garach A, Álvarez-Bermúdez MD, Moreno-Indias I, Tinahones FJ. Gut microbiota of patients with type 2 diabetes and gastrointestinal intolerance to metformin differs in composition and functionality from tolerant patients. Biomed Pharmacother. 2022;145:112448. doi:10.1016/j.biopha.2021.112448
   PubMed Web of Science ®Google Scholar
• Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262–266. doi:10.1038/nature15766
   PubMed Web of Science ®Google Scholar
• Bryrup T, Thomsen CW, Kern T, et al. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study. Diabetologia. 2019;62(6):1024–1035. doi:10.1007/s00125-019-4848-7
   PubMed Web of Science ®Google Scholar
• Rosario D, Benfeitas R, Bidkhori G, et al. Understanding the representative gut microbiota dysbiosis in metformin-treated type 2 diabetes patients using genome-scale metabolic modeling. Front Physiol. 2018;9:775. doi:10.3389/fphys.2018.00775
   PubMed Web of Science ®Google Scholar
• Degaga A, Sirgu S, Huri HZ, et al. Association of Met420del variant of metformin transporter gene SLC22A1 with metformin treatment response in Ethiopian patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2023;16:2523–2535. doi:10.2147/DMSO.S426632
   PubMedGoogle Scholar
• Du Plessis M, Pearce B, Jacobs C, Hoosain N, Benjeddou M. Genetic polymorphisms of the organic cation transporter 1 gene (SLC22A1) within the Cape Admixed population of South Africa. Mol Biol Rep. 2015;42(3):665–672. doi:10.1007/s11033-014-3813-2
   PubMed Web of Science ®Google Scholar
• Jacobs C, Pearce B, Du Plessis M, Hoosain N, Benjeddou M. Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa. Genet Mol Biol. 2014;37(2):350–359.
   PubMed Web of Science ®Google Scholar
• Bennett PH. Impact of the new WHO classification and diagnostic criteria. Diabetes Obes Metab. 1999;1(Suppl 2):S1–6. doi:10.1046/j.1463-1326.1999.0010s2001.x
   PubMedGoogle Scholar
• Wang H, Chow SC. Sample size calculation for comparing proportions. In: Wiley Encyclopedia of Clinical Trials. John Wiley & Sons, Ltd; 2007. doi10.1002/9780471462422.eoct005
   Google Scholar
• Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137(1):25–33. doi:10.7326/0003-4819-137-1-200207020-00009
   PubMed Web of Science ®Google Scholar
• Dujic T, Causevic A, Bego T, et al. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. Diabet Med J Br Diabet Assoc. 2016;33(4):511–514. doi:10.1111/dme.13040
   PubMed Web of Science ®Google Scholar
• Dawed AY, Zhou K, van Leeuwen N, et al. Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and gastrointestinal intolerance to metformin in type 2 diabetes: an IMI direct study. Diabetes Care. 2019;42(6):1027–1033. doi:10.2337/dc18-2182
   PubMed Web of Science ®Google Scholar
• Lim MT, Ab Rahman N, Teh XR, et al. Optimal cut-off points for adherence measure among patients with type 2 diabetes in primary care clinics: a retrospective analysis. Ther Adv Chronic Dis. 2021;12:2040622321990264. doi:10.1177/2040622321990264
   Web of Science ®Google Scholar
• Seid MA, Akalu Y, Gela YY, et al. Microvascular complications and its predictors among type 2 diabetes mellitus patients at Dessie town hospitals, Ethiopia. Diabetol Metab Syndr. 2021;13:86. doi:10.1186/s13098-021-00704-w
   PubMed Web of Science ®Google Scholar
• Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and Type 2 Diabetes. Diabetes Care. 2010;33(12):e147–e167. doi:10.2337/dc10-9990
   PubMed Web of Science ®Google Scholar
• Miks SBJ Gene-Calc [Computer software]; 2018. Available from: www.gene-calc.pl. Accessed April 28, 2023.
   Google Scholar